Heidelberg Pharma AG (HPHA) AI Stock Analysis

• Market Cap: €138.95M
• Dividend Yield: N/A
• Average Volume (3M): 8.68K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.95
• Revenue Growth: -64.15%
• EPS Growth: -39.31%
• Country: DE
• Employees: 105
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.14
• Shares Outstanding: 46,784,317
• 10 Day Avg. Volume: 4,439
• 30 Day Avg. Volume: 8,684
• PEG Ratio: 1.27
• Price to Book (P/B): 3.62
• Price to Sales (P/S): 16.33
• P/FCF Ratio: -3.72
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): -0.54
• Revenue Forecast (FY): €7.30M

• Rating: 39 Underperform
• Price Target: €3.00 ▲(0.67% Upside)

Heidelberg Pharma AG's overall stock score is heavily impacted by its poor financial performance, with significant losses and liquidity concerns. Technical analysis indicates bearish momentum, and valuation metrics are unattractive. These factors combine to result in a low overall score.

Heidelberg Pharma AG Business Overview & Revenue Model

Company Description

Heidelberg Pharma AG (HPHA) is a biopharmaceutical company based in Germany specializing in the development of innovative therapeutics for the treatment of cancer. The company focuses on its proprietary ATAC technology (Antibody Targeted Amanitin Conjugates), which enables the targeted delivery of potent therapeutic agents directly to cancer cells. This approach is designed to minimize damage to healthy tissue while maximizing the efficacy of the treatment. HPHA operates primarily in the biopharmaceutical sector, with a strong emphasis on research and development of novel therapies that leverage its unique technology platform.

How the Company Makes Money

Heidelberg Pharma AG generates revenue through multiple channels, primarily focusing on the development and commercialization of its proprietary drug candidates. The company's revenue model includes funding from partnerships with other pharmaceutical firms, where they collaborate on the development of ATAC-based therapies. These partnerships often involve upfront payments, milestone payments upon achieving specific development goals, and royalties on future sales of products that result from these collaborations. Additionally, HPHA may receive funding from government grants and venture capital investments aimed at advancing its research initiatives. The company's potential for earnings is significantly influenced by the successful advancement of its drug candidates through clinical trials and subsequent commercialization.

Heidelberg Pharma AG Financial Statement Overview

Summary

Heidelberg Pharma AG faces significant financial challenges, with declining revenues and substantial losses. Negative profit margins and return on equity reflect poor profitability. Despite low leverage indicating some financial stability, negative cash flows highlight liquidity concerns.

Income Statement

Heidelberg Pharma AG's income statement reveals significant challenges. The company has experienced a sharp decline in revenue, with a TTM revenue growth rate of -38.95%. Profitability metrics are concerning, with negative net profit margins and EBIT margins indicating substantial losses. Despite a strong gross profit margin of 76.91%, the company's high operating expenses are eroding profitability.

Balance Sheet

The balance sheet shows a relatively low debt-to-equity ratio of 0.0066, indicating low leverage, which is a positive aspect. However, the return on equity is significantly negative at -84.55%, reflecting poor profitability and potential challenges in generating returns for shareholders. The equity ratio is not provided, but the low leverage suggests some stability in capital structure.

Cash Flow

Cash flow analysis highlights negative operating cash flow and free cash flow, with a slight decrease in free cash flow growth. The operating cash flow to net income ratio is negative, indicating cash flow challenges. However, the free cash flow to net income ratio is slightly above 1, suggesting that free cash flow is slightly better aligned with net income despite the losses.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	4.18M	6.85M	9.86M	18.51M	1.75M	8.49M
Gross Profit	3.22M	4.20M	6.61M	13.83M	-2.96M	2.89M
EBITDA	-22.43M	-18.37M	-18.71M	-16.19M	-24.83M	-17.55M
Net Income	-23.31M	-19.38M	-20.35M	-19.70M	-26.63M	-18.37M
Balance Sheet
Total Assets	62.45M	60.72M	70.35M	100.58M	21.73M	19.61M
Cash, Cash Equivalents and Short-Term Investments	33.25M	29.42M	43.44M	81.33M	6.14M	4.98M
Total Debt	37.67M	21.97M	5.83M	15.98M	10.63M	202.68K
Total Liabilities	43.94M	29.85M	21.01M	33.94M	15.03M	6.73M
Stockholders Equity	18.52M	30.87M	49.34M	66.64M	6.70M	12.88M
Cash Flow
Free Cash Flow	-27.21M	-30.04M	-34.63M	-9.48M	-28.00M	-19.33M
Operating Cash Flow	-26.78M	-29.59M	-33.67M	-8.86M	-26.61M	-17.89M
Investing Cash Flow	-445.00K	-449.13K	5.85M	-597.57K	-1.40M	-1.29M
Financing Cash Flow	17.96M	16.08M	-10.05M	84.00M	29.17M	14.29M

Heidelberg Pharma AG Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.98
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:HPHA, the sentiment is Negative. The current price of 2.98 is below the 20-day moving average (MA) of 3.03, below the 50-day MA of 3.11, and below the 200-day MA of 3.41, indicating a bearish trend. The MACD of -0.04 indicates Negative momentum. The RSI at 42.87 is Neutral, neither overbought nor oversold. The STOCH value of 33.41 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DE:HPHA.

Heidelberg Pharma AG Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ILM1	70 Outperform	$312.70M	16.61	4.18%	―	9.27%	65.65%
FYB	55 Neutral	€373.78M	-2.20	-34.48%	―	-14.84%	-338.52%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BIO	51 Neutral	€1.35B	-61.38	―	0.11%	-18.82%	-113.85%
BNN	48 Neutral	€49.81M	-3.65	-111.86%	―	-4.90%	-69.80%
HPHA	39 Underperform	€138.95M	―	-112.95%	―	-64.15%	-39.31%